Amended Current Report Filing (8-k/a)
September 15 2017 - 4:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 13, 2017
MEDIFAST, INC.
(Exact name of registrant as specified in
its Charter)
Delaware
|
|
001-31573
|
|
13-3714405
|
(State or other jurisdiction
|
|
(Commission file number)
|
|
(IRS Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
3600 Crondall Lane, Owings Mills,
Maryland 21117
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number, including
area code:
(410) 581-8042
N/A
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
|
¨
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
¨
|
Explanatory Note
This Form 8-K/A amends
the Form 8-K furnished by Medifast Inc. (the “Company”) on September 13, 2017 (the “Original Form 8-K”),
in which the Company included as an exhibit to the Original Form 8-K an investor presentation that from time to time may be used
in conversations and meetings with analysts, investors and others. This Form 8-K/A is being furnished for the purpose of correcting
the “Date of Report” of the Original Form 8-K and providing typographical corrections and immaterial updates to slides
6, 8, 10, 16, 18, and 25 of the presentation.
Item 7.01.
|
Regulation FD Disclosure.
|
Medifast, Inc. is posting
an updated investor presentation to the Investor Relations section of the Company’s website at https://ir.medifastnow.com/.
The Company may use the investor presentation from time to time in conversations and meetings with analysts, investors and others.
A copy of the
above referenced updated presentation is furnished in its entirety as Exhibit 99.1 to this Current Report on Form 8-K/A. The
information in this Current Report on Form 8-K/A, including Exhibit 99.1 hereto, shall not be deemed to be
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any
filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
Signature
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MEDIFAST, INC.
|
|
|
|
|
|
By:
|
/s/ Jason L. Groves
|
|
|
Jason L. Groves, Esq.
Executive Vice President and General Counsel
|
|
|
|
Dated: September 15, 2017
|
|
EXHIBIT INDEX
Medifast (NYSE:MED)
Historical Stock Chart
From Aug 2024 to Sep 2024
Medifast (NYSE:MED)
Historical Stock Chart
From Sep 2023 to Sep 2024